A startup developing artificial red blood cells coated with a lipid bilayer. These cells possess oxygen-carrying capacity equivalent to red blood cells and enable long-term storage, aiming to revolutionize transfusion medicine through stable blood transfusions in veterinary medicine and future practical application in human healthcare.
We are developing generative AI to support decision-making for healthcare professionals and the general public. Specifically, Cubec functions as a learning support tool that answers questions arising in physicians’ daily practice, and it generates revenue by providing pharmaceutical companies with high-precision data on physician needs. We are planning a phased business rollout, with the ultimate goal of implementing as a Software as a Medical Device (SaMD) that supports physicians’ clinical decision-making.
A startup originating from the University of Tokyo and the University of Tsukuba, possessing proprietary technology for selectively amplifying hematopoietic stem cells in vitro. It aims to realize next-generation regenerative medicine through cell and gene therapies for blood disorders and genetic diseases, as well as vascular regeneration technology.
KDDD (Kyoto Drug Discovery and Development) is a spin-off company from Kyoto University. Our project is based on a result of research by Department of Ophthalmology Kyoto University and Graduate School of Biostudies. We sincerely aim to develop an innovative agent effective for various INCURABLE or INTRACTABLE eye diseases, especially CRAO, Retinal Pigmentosa, AMD and Glaucoma.
Bioaccell is a Kyoto-based contract cell processing company that cultivates therapeutic immune cells for medical institutions. It provides certified cell culture services for cancer immunotherapy.